Literature DB >> 17927588

HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study.

M E Nowee1, J C Dorsman, J M J Piek, V M Kosma, K Hämäläinen, R H M Verheijen, P J van Diest.   

Abstract

AIMS: To determine expression of p53, HER-2/neu and p27(Kip1) in serous Fallopian tube carcinoma (FTC) in relation to stage and grade, and to investigate DNA copy number changes of HER-2 and P27KIP1 as a potential mechanism of altered expression status. METHODS AND
RESULTS: Immunohistochemistry was performed on 28 serous FTCs and 10 normal Fallopian tubes. p53 protein accumulated and p27(Kip1) was down-regulated significantly in early-stage FTCs compared with normal Fallopian tubes. HER-2/neu overexpression was absent in normal Fallopian tubes and in all stage I FTCs (n = 6) but present in 57% (12/21) of advanced-stage FTCs. No differences in expression between grade 2 and 3 tumours were detected. HER-2 gain/amplification was found by array comparative genomic hybridization in 23% (3/13) of analysed FTCs and all showed overexpression. HER-2/neu overexpression also occurred without DNA copy number changes in three other cases. For p27(Kip1), expression and DNA copy number were unrelated.
CONCLUSIONS: p53 accumulation and p27(Kip1) down-regulation seem to be early events in Fallopian tube carcinogenesis. HER-2/neu showed overexpression, caused by gain/amplification in 50%, and may be involved in progression of FTC. These data contribute to a better understanding of the molecular carcinogenesis of FTC and to possible new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17927588     DOI: 10.1111/j.1365-2559.2007.02850.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

Review 1.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 2.  Evaluating the progenitor cells of ovarian cancer: analysis of current animal models.

Authors:  Shelby M King; Joanna E Burdette
Journal:  BMB Rep       Date:  2011-07       Impact factor: 4.778

3.  Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.

Authors:  Russell Vang; Kala Visvanathan; Amy Gross; Emily Maambo; Mamta Gupta; Elisabetta Kuhn; Rose Fanghong Li; Brigitte M Ronnett; Jeffrey D Seidman; Anna Yemelyanova; Ie-Ming Shih; Patricia A Shaw; Robert A Soslow; Robert J Kurman
Journal:  Int J Gynecol Pathol       Date:  2012-05       Impact factor: 2.762

4.  The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.

Authors:  Gulay Turan; Ceyda Sancakli Usta; Akin Usta; Mehmet Kanter; Lema Tavli; Meric Karacan; Cetin Celik; Metin Eser
Journal:  J Mol Histol       Date:  2014-08-09       Impact factor: 2.611

5.  Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.

Authors:  Cathy B Moelans; Paul J van Diest; Anya N A Milne; G Johan A Offerhaus
Journal:  Patholog Res Int       Date:  2010-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.